$2995 | Single User
$5990 | Site License
$8985 | Enterprise License

Multiple Myeloma - Current and Future Players
[Published by Global Data]

Published by Global Data: 01 Nov 2015 | 27220 | In Stock
Related Topics: Multiple Myeloma , Myeloma

Introduction

Multiple Myeloma - Current and Future Players

Summary

GlobalData has released its pharma report, “Multiple Myeloma - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Myeloma Market. The report identifies and analyses the key companies shaping and driving the global Multiple Myeloma market. The report provides insight into the competitive Multiple Myeloma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Multiple Myeloma

- Competitor assessment

- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

- Strategic assessment of Multiple Myeloma sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Multiple Myeloma market

- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

- Create an effective counter-strategy to gain a competitive advantage against those currently in the market

- What’s the next big thing in the global Multiple Myeloma market landscape? Identify, understand and capitalize

Table of Contents
for Multiple Myeloma - Current and Future Players [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 4

    1.2 List of Figures 5

    2 Introduction 6

    2.1 Catalyst 6

    2.2 Related Reports 7

    2.3 Upcoming Related Reports 7

    3 Market Outlook 8

    3.1 Global Markets 8

    3.1.1 Forecast 8

    3.1.2 Drivers - Global Issues 15

    3.1.3 Barriers - Global Issues 16

    4 Current and Future Players 18

    4.1 Overview and Trends in Corporate Strategy 18

    4.2 Company Profiles 21

    4.2.1 Millennium Pharmaceuticals/Takeda 21

    4.2.2 Celgene 23

    4.2.3 Onyx Pharmaceuticals/Amgen 25

    4.2.4 Novartis 26

    4.2.5 AbbVie 28

    4.2.6 Bristol-Myers Squibb 29

    4.2.7 Janssen 30

    5 Appendix 32

    5.1 Bibliography 32

    5.2 Abbreviations 54

    5.3 Methodology 58

    5.4 Forecasting Methodology 58

    5.4.1 Diagnosed Multiple Myeloma Patients 58

    5.4.2 Percent of Drug-Treated Patients 59

    5.4.3 Drugs Included in Each Therapeutic Class 59

    5.4.4 Launch and Patent Expiry Dates 60

    5.4.5 General Pricing Assumptions 61

    5.4.6 Individual Drug Assumptions 62

    5.4.7 Pricing of Pipeline Agents 69

    5.4.8 Generic Erosion 76

    5.5 Primary Research - KOLs Interviewed for this Report 77

    5.6 Primary Research - High-Prescriber Survey 79

    5.7 About the Authors 80

    5.7.1 Analyst 80

    5.7.2 Therapy Director 80

    5.7.3 Epidemiologist 80

    5.7.4 Global Head of Healthcare 81

    5.8 About GlobalData 82

    5.9 Disclaimer 82

List Of Tables
in Multiple Myeloma - Current and Future Players [Published by Global Data]

1.1 List of Tables

Table 1: Annual Global Sales ($m) for Multiple Myeloma by Region, 2013-2023 9

Table 2: Annual Global Sales ($m) for Multiple Myeloma by Drug, 2013-2023 12

Table 3: Global Multiple Multiple Myeloma - Drivers, 2013-2023 15

Table 4: Global Multiple Multiple Myeloma - Barriers, 2013-2023 16

Table 5: Key Companies in the Multiple Myeloma Market Across the 8MM, 2013-2023 19

Table 6: Millennium Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 23

Table 7: Celgene’s Multiple Myeloma Therapy Portfolio Assessment, 2015 25

Table 8: Onyx Pharmaceuticals Multiple Myeloma Therapy Portfolio Assessment, 2015 26

Table 9: Novartis’ Multiple Myeloma Therapy Portfolio Assessment, 2015 28

Table 10: AbbVie’s Multiple Myeloma Therapy Portfolio Assessment, 2015 29

Table 11: BMS’ Multiple Myeloma Therapy Portfolio Assessment, 2015 30

Table 12: Janssen’s Multiple Myeloma Therapy Portfolio Assessment, 2015 31

Table 13: Multiple Myeloma Diagnosed Incidence, 2013-2023 59

Table 14: Multiple Myeloma Drugs and Pipeline agents, Launch Dates 60

Table 15: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries 61

Table 16: Average Cost of Therapy for Velcade 63

Table 17: Average Duration of Treatment (Weeks) for Velcade 63

Table 18: Average Cost of Therapy for Kyprolis ($) 65

Table 19: Average Duration of Treatment (Weeks) for Kyprolis 65

Table 20: Average Cost of Therapy for Revlimid ($) 66

Table 21: Average Duration of Treatment (Weeks) for Revlimid 67

Table 22: Average Cost of Therapy for Pomalyst/Imnovid ($) 68

Table 23 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid 68

Table 24: Average Cost of Therapy for Farydak ($) 69

Table 25: Duration of Treatment (Weeks) for Farydak 70

Table 26: Average Cost of Therapy for Ixazomib ($) 71

Table 27: Duration of Treatment (Weeks) for Ixazomib 71

Table 28: Average Cost of Therapy for Empliciti ($) 72

Table 29: Duration of Treatment (Weeks) for Empliciti 73

Table 30: Average Cost of Therapy for Daratumumab ($) 74

Table 31: Duration of Treatment (Weeks) for Daratumumab 75

Table 32: Average Cost of Therapy for Daratumumab ($) 76

Table 33: Duration of Treatment (Weeks) for Daratumumab 76

Table 34: Numbers of Prescribers Surveyed in Each Country 79

List Of Figures, Charts and Diagrams
in Multiple Myeloma - Current and Future Players [Published by Global Data]

1.2 List of Figures

Figure 1: Annual Global Sales for Multiple Myeloma by Region, 2013-2023 10

Figure 2: Annual Global Sales for Multiple Myeloma by Region - 2013, 2023 11

Figure 3: Annual Global Sales for Multiple Myeloma by Drug, 2013-2023 13

Figure 4: Global Sales for Multiple Myeloma by Drug, 2013 - 2023 14

Figure 5: Global Sales ($m) of Branded Products for Multiple Myeloma by Company, 2013 - 2023 20

Figure 6: Company Portfolio Gap Analysis in Multiple Myeloma, 2013-2023 21

Additional Details

Publisher

Global Data

Publisher Information

Reference

27220 | GDHC1051FPR

Number of Pages

83

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Global Data

Download Free Report Summary PDF

Multiple Myeloma - Current and Future Players [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...